Long-acting preparations of exenatide

Exenatide has been widely used for the treatment of type 2 diabetes mellitus. However, its short plasma half-life of 2.4 hours has limited its clinical application. The exenatide products on the market, twice-daily Byetta™ and once-weekly Bydureon™ (both Amylin Pharmaceuticals, San Diego, CA, USA),...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Yunpeng, Wei, Liangming, Ma, Liuqing, Huang, Xiwen, Tao, Anqi, Liu, Zhenguo, Yuan, Weien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771853/
https://www.ncbi.nlm.nih.gov/pubmed/24039406
http://dx.doi.org/10.2147/DDDT.S46970
_version_ 1782284234287742976
author Cai, Yunpeng
Wei, Liangming
Ma, Liuqing
Huang, Xiwen
Tao, Anqi
Liu, Zhenguo
Yuan, Weien
author_facet Cai, Yunpeng
Wei, Liangming
Ma, Liuqing
Huang, Xiwen
Tao, Anqi
Liu, Zhenguo
Yuan, Weien
author_sort Cai, Yunpeng
collection PubMed
description Exenatide has been widely used for the treatment of type 2 diabetes mellitus. However, its short plasma half-life of 2.4 hours has limited its clinical application. The exenatide products on the market, twice-daily Byetta™ and once-weekly Bydureon™ (both Amylin Pharmaceuticals, San Diego, CA, USA), are still not perfect. Many researchers have attempted to prolong the acting time of exenatide by preparing sustained-release dosage forms, modifying its structure, gene therapies, and other means. This review summarizes recent advances in long-acting exenatide preparations.
format Online
Article
Text
id pubmed-3771853
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-37718532013-09-13 Long-acting preparations of exenatide Cai, Yunpeng Wei, Liangming Ma, Liuqing Huang, Xiwen Tao, Anqi Liu, Zhenguo Yuan, Weien Drug Des Devel Ther Review Exenatide has been widely used for the treatment of type 2 diabetes mellitus. However, its short plasma half-life of 2.4 hours has limited its clinical application. The exenatide products on the market, twice-daily Byetta™ and once-weekly Bydureon™ (both Amylin Pharmaceuticals, San Diego, CA, USA), are still not perfect. Many researchers have attempted to prolong the acting time of exenatide by preparing sustained-release dosage forms, modifying its structure, gene therapies, and other means. This review summarizes recent advances in long-acting exenatide preparations. Dove Medical Press 2013-09-05 /pmc/articles/PMC3771853/ /pubmed/24039406 http://dx.doi.org/10.2147/DDDT.S46970 Text en © 2013 Cai et al. This work is published by Dove Medical Press Ltd, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Ltd, provided the work is properly attributed.
spellingShingle Review
Cai, Yunpeng
Wei, Liangming
Ma, Liuqing
Huang, Xiwen
Tao, Anqi
Liu, Zhenguo
Yuan, Weien
Long-acting preparations of exenatide
title Long-acting preparations of exenatide
title_full Long-acting preparations of exenatide
title_fullStr Long-acting preparations of exenatide
title_full_unstemmed Long-acting preparations of exenatide
title_short Long-acting preparations of exenatide
title_sort long-acting preparations of exenatide
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771853/
https://www.ncbi.nlm.nih.gov/pubmed/24039406
http://dx.doi.org/10.2147/DDDT.S46970
work_keys_str_mv AT caiyunpeng longactingpreparationsofexenatide
AT weiliangming longactingpreparationsofexenatide
AT maliuqing longactingpreparationsofexenatide
AT huangxiwen longactingpreparationsofexenatide
AT taoanqi longactingpreparationsofexenatide
AT liuzhenguo longactingpreparationsofexenatide
AT yuanweien longactingpreparationsofexenatide

Ejemplares similares